Monday, December 23, 2013

The Motley Fool: Bristol Myers Squibb and AstraZeneca: A Big Break-Up in the Diabetes Space

Breaking up is supposed to be hard to do, but it happens often enough in the diabetes space. After a disappointing run with multiple drugs and rising FDA demands for new drugs, Bristol-Myers Squibb (NYSE: BMY  ) and AstraZeneca (NYSE: AZN  ) have reached an agreement to end their diabetes joint venture, with AstraZeneca buying out Bristol-Myers' stake. Although there are ways in which this deal can work out positively for AstraZeneca, competition from the likes of Novo Nordisk (NYSE: NVO  ) and Eli Lilly (NYSE: LLY  ) makes this a risky move for AstraZeneca and likely a savvy deal for Bristol-Myers.

Please continue here:
Bristol Myers Squibb and AstraZeneca: A Big Break-Up in the Diabetes Space

No comments: